KELLIE GROVE: Open Payments
NPI 1811472681 · TUPELO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,226 in 164 payments from 26 companies in 2025. Trend: 2023 $1,615 · 2024 $2,568 · 2025 $3,226
Food & beverage: $3,215Education: $11
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 28 | $646 |
| GlaxoSmithKline, LLC. | 36 | $479 |
| Merck Sharp & Dohme LLC | 12 | $243 |
| GENZYME CORPORATION | 8 | $204 |
| HARMONY BIOSCIENCES LLC | 7 | $200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $193 |
| Regeneron Healthcare Solutions, Inc. | 8 | $179 |
| JAZZ PHARMACEUTICALS INC. | 6 | $143 |
| Electromed, Inc. | 8 | $117 |
| Grifols USA, LLC | 4 | $115 |
Products named: DUPIXENT, BREZTRI, FASENRA, NUCALA, TRELEGY ELLIPTA, WAKIX, XYWAV, ZERBAXA.
Industry payments across MS — which companies pay providers there.
